Connect with us


Senate Dems blast HHS appointee’s anti-LGBT ‘bigoted statements’

Severino opposed trans health care, now charged with defending trans health



Roger Severino, gay news, Washington Blade

Roger Severino was appointed assistant secretary of human rights at HHS. (Image courtesy C-Span)

A group of a dozen Senate Democrats is calling on the Department of Health & Human Services to answer questions about “deep concerns” they have with the appointment of Roger Severino as assistant secretary for civil rights, citing “bigoted statements” he made against LGBT people.

In a two-page letter obtained by the Washington Blade, the 12 Senate Democrats say past statements Severino made against LGBT people, including about transgender people’s access to transition-related care, as well as his comments against Planned Parenthood and women’s access to abortion “raise serious questions about his ability to oversee the Office of Civil Rights.”

“Mr. Severino has a long history of making bigoted statements toward lesbian, gay, bisexual, and transgender people and attacking women’s access to health care services and reproductive rights,” the letter says. “His appointment raises deep concerns about the employment decisions and hiring practices being established by the Trump Administration.”

Signing the letter are Sens. Patty Murray (D-Wash.), Tammy Baldwin (D-Wis.), Kirsten Gillibrand (D-N.Y.), Richard Blumenthal (D-Conn.), Cory Booker (D-N.J.), Sherrod Brown (D-Ohio), Edward Markey (D-Mass.), Bernie Sanders (I-Vt.), Patrick Leahy (D-Vt.), Sheldon Whitehouse (D-R.I.), Jeff Merkley (D-Ore.) and Tim Kaine (D-Va.).

Upon news that Severino — who until recently was an analyst and blogger with the anti-LGBT Heritage Foundation — had landed an appointment as HHS assistant secretary for civil rights, LGBT rights supporters denounced the move as tantamount to appointing the proverbial fox to guard a henhouse.

In the role, Severino is charged with defending the civil rights of Americans in health care, including transgender people. But at the Heritage Foundation, Severino wrote blog posts demeaning transgender people and opposing the Obama administration’s efforts to ensure they have access to transition-related care.

After the Obama administration issued a regulation ensuring non-discrimination in health care for transgender people under Section 1557 of the Affordable Care Act, which bars discrimination on the basis of sex, Severino wrote the rule would “create special privileges based on gender identity.”

Because the regulation ensures transgender people access to gender reassignment surgery, he wrote it would “force doctors to perform sex-reassignment surgeries,” erroneously suggesting it would require doctors to perform the procedure even when medically unnecessary.

It should be noted U.S. Judge Reed O’Connor issued an injunction in December barring the U.S. government from enforcing the regulation, which not only barred discrimination against transgender people, but also women who have had abortions. The U.S. Justice Department missed a deadline under U.S. Attorney General Jeff Sessions to appeal that decision to the U.S. Fifth Circuit Court of Appeals.

As cited in the letter, Severino also came out in opposition to the lawsuit filed by former U.S. Attorney General Loretta Lynch against North Carolina’s House Bill 2, which barred cities from enacting pro-LGBT ordinances and transgender people from using the restroom in bathroom and government buildings consistent with their gender identity. (A replacement law signed by North Carolina Gov. Roy Cooper, a Democrat, keeps certain elements of the discriminatory measure in place.)

“The radical left is using government power to coerce everyone, including children, into pledging allegiance to a radical new gender ideology over and above their right to privacy, safety, and religious freedom,” Severino wrote.

The letter from Senate Democrats also takes issue with Severino’s support for Kim Davis, the clerk in Rowan County, Ky., who instituted a “no licenses” policy in her office after the U.S. Supreme Court issued an order granting same-sex couples the right to obtain marriage licenses nationwide.

In addition to citing concerns about Severino’s writings on LGBT people, Senate Democrats also raised concerns about his opposition to access to abortion.

Severino, as the letter notes, objected to a U.S. Supreme Court ruling against a Texas anti-abortion law and accused Planned Parenthood of “every trick in the book to get federal money by trying to pretend that its core business is anything but industrial-scale abortion.”

As a result of Severino’s appointment and past writings, the Senate Democrats ask HHS to respond to four questions about his appointment by a deadline of April 21:

1. How does the Department plan to promote a diverse and inclusive workforce free of prejudice or malice?
2. What are the Department’s vetting procedures for political appointees?
3. What are the Department’s plans to handle reports of inappropriate communications or behavior from staff?
4. Will Mr. Severino, as well as any other department appointee who has worked against the ACA’s nondiscrimination protections, be asked to recuse him- or herself from any decisions related to the enforcement of Section 1557?

The Washington Blade has placed a request with HHS seeking comment on the Senate Democrats’ letter.

Continue Reading


  1. Jay Phelps

    April 10, 2017 at 5:30 pm

    Finally some Democrats are raising concerns about Trump’s anti-LGBT choices! I don’t think this administration has appointed even one person who’s not rabidly antigay.

    • Mark Cichewicz

      April 14, 2017 at 12:29 pm

      And it sucks that some LGBTQ Americans voted for this. Boycott Republicans.

Leave a Reply

Your email address will not be published. Required fields are marked *


Md. biotech company’s HIV cure project clears first hurdle

‘We all have something to be excited about’



HIV cure, gay news, Washington Blade
‘We all have something to be excited about,’ said AGT CEO Jeff Galvin.

American Gene Technologies, the Rockville, Md., biotech company, has announced that the first patient to receive its genetically engineered treatment therapy aimed at curing people of HIV/AIDS encountered no adverse side effects from the treatment.

In an Aug. 2 statement, AGT said that based on the data obtained from Patient One in its Phase 1 human trial of its HIV treatment called AGT103-T, the U.S. Food and Drug Administration’s Data and Safety Monitoring Board voted unanimously to allow AGT to continue its HIV cure program without modification.

“The AGT103-T pipeline is a therapy for treating HIV disease,” the company’s statement says. “The therapy is designed to induce durable viral suppression by delivering therapeutic genes to the recipient’s immune cells,” it says. “The resulting immune cells are expected to survive attack by HIV and durably suppress the virus at undetectable levels without the need for antiretroviral treatment.”

The thumbs up decision by the Data and Safety Monitoring Board allows the company to continue its clinical trial with more participants to further confirm the HIV treatment’s safety outcome. The next phase in the trials will be to determine the treatment’s effectiveness in fully protecting the human body from HIV.

“We have six more patients,” said AGT CEO Jeff Galvin in referring to the patients who will be tested for possible adverse side effects in the coming weeks. Galvin spoke at a July 29 gathering to celebrate the success of Patient One at AGT’s headquarters offices in Rockville.

“If this works, they will be permanently immune from HIV,” he said. “Just think what this can do with the epidemic. We all have something to be excited about,” he told the gathering of about 100 people.

“Keep your fingers crossed. Let’s all keep hoping and praying,” Galvin said. “We will know by the middle of next year,” he said, referring to when the human trials will likely determine whether the AGT103-T treatment, which has successfully stopped HIV from infecting human cells in laboratory experiments, will work just as effectively on people with HIV.

Continue Reading

Cannabis Culture

Cannabis Culture

National Cannabis Festival moved to Sept. 19



National Cannabis Festival, gay news, Washington Blade
Due to COVID-19, the National Cannabis Festival was moved to September. (Photo courtesy National Cannabis Festival)

National Cannabis Festival moved to Sept. 19

The fifth annual National Cannabis Festival, originally scheduled for April, has been postponed to Saturday, Sept. 19 at RFK Festival Grounds in Washington, D.C. The move was precipitated by the coronavirus pandemic.

Organizers have announced a full day of live entertainment, including Method Man & Redman, Young M.A., Backyard Band, Antibalas and the Archives.

In the meantime, organizers will host the Highstream 420 Festival on April 20. Visit for information on how to participate.

You must be 21 and older with valid government-issued identification to attend the National Cannabis Festival. The National Cannabis Festival was founded in 2015 by a group of cannabis enthusiasts to celebrate marijuana legalization across the country.

Cannabis advocate dies from COVID-19 in Colo.

COLORADO SPRINGS, Colo. — Charlotte Figi, who brought international attention to the use of CBD-dominant extracts as anti-seizure agents, has passed away due to complications related to the COVID-19 virus, according to multiple news reports. She was 13 years old.

Charlotte Figi suffered from Dravet syndrome, a rare and highly debilitating form of childhood epilepsy. After conventional therapies failed to stabilize her condition, her parents eventually experimented with the use of cannabidiol-rich extracts. The administration of CBD extracts was associated with a dramatic reduction in Charlotte’s seizure frequency, and her case was eventually profiled in 2013 in a widely viewed CNN documentary hosted by Dr. Sanjay Gupta.

Commenting on her untimely passing, NORML Deputy Director Paul Armentano said: “Charlotte Figi personalized this issue in a way that few others have, and her story humanized the medical cannabis fight to such a degree that many politicians could no longer ignore it. There is little doubt that Charlotte’s story emboldened lawmakers in several southern and mid-western states to finally move forward to recognize the need for CBD, and in some cases, whole-plant cannabis access.”

In June 2018, the U.S. Food and Drug Administration approved Epidiolex, a prescription medicine containing a standardized formulation of plant-derived cannabidiol for the explicit treatment of two rare forms of severe epilepsy: Lennox-Gastaut syndrome and Dravet syndrome.

2 of 5 dispensaries shut down in Iowa

DES MOINES, Iowa — Two of the state’s five licensed medical cannabis access facilities have shut their doors, according to media reports.

The closures leave only three operating dispensaries left in the state. Iowa has only one licensed cultivation center. According to the Iowa Department of Health, an estimated 4,300 are registered to access cannabis extract products. Under state law, those extracts must not contain percentages of THC in excess of three percent. Legislation advanced by lawmakers last year to remove the low-THC cap was ultimately vetoed by Republican Gov. Kim Reynolds.

Following the recent closures, Democratic state Sen. Joe Bolkom said: “Iowa has the most bureaucratic, expensive, and ineffective program in the country and it just got worse… More evidence is now in with two of our dispensaries essentially going out of business because it’s economically not feasible.”

Under the state’s access law, there can be no more than five licensed dispensaries operating in the state at one time.

Fewer vaping illnesses in states with legal cannabis

Bloomington, Ind. — Incidences of the vaping-related lung illness EVALI (e-cigarette or vaping product use-associated lung injury) are primarily concentrated to jurisdictions where adult-use cannabis consumption is prohibited, according to data published in the Journal of the American Medical Association (JAMA) Network Open.

Commenting on the findings, NORML Executive Director Erik Altieri said, “These findings come as little surprise. In jurisdictions where cannabis is legally regulated, consumers gravitate toward the above-ground retail marketplace where they can access lab-tested products manufactured by licensed businesses.”

He added, “Just like alcohol prohibition gave rise to the illicit production of dangerous ‘bathtub gin,’ marijuana prohibition provides bad actors, not licensed businesses, the opportunity to fulfill consumers’ demand – sometimes with tragic results.”

According to the U.S. Centers for Disease Control and Prevention, nearly 3,000 people have sought hospitalization because of the illness, which peaked last September, and nearly 70 people died as a result of it. In November, the CDC publicly identified vitamin E acetate – a diluting agent sometimes present in counterfeit, unregulated vape pen products – as a primarily “culprit” in the outbreak.

Writing on Monday in the journal JAMA Network Open, researchers affiliated with Indiana University reported that last year’s sudden outbreak of EVALI cases was not driven by either state-level differences or prevalence in e-cigarette use. Rather, they reported that cases “were concentrated in states where consumers do not have legal access to recreational marijuana dispensaries… One possible inference from our results is that the presence of legal markets for marijuana has helped mitigate or may be protective against EVALI.”

A previous analysis of EVALI prevalence in legal cannabis markets versus illegal markets by drew a similar conclusion.

In a statement to the online news site, the study’s lead author said that the team’s findings are “consistent with the hypothesis that people have demand for marijuana products, and in states where they don’t have access to them in this regulatory fashion, they end up purchasing them elsewhere.”

Cannabis Culture news in the Blade is provided in partnership with NORML. Visit for more information.

Continue Reading


Skin cancer is greater risk for gay, bi men

3.3 million diagnosed each year: American Cancer Society



tanning, Skin Cancer, gay news, Washington Blade
Researchers suggest that more frequent use of tanning beds by gay and bi men may play a role.

SAN FRANCISCO — Gay and bi men are more likely to develop skin cancer than straight men, according to a new study, the Bay Area Reporter reports. The research also showed that bi women have a lower rate than straight women. A companion study revealed a higher skin cancer rate among gender-nonconforming people.

Although these studies were unable to evaluate specific risk factors, the researchers suggested that more frequent use of tanning beds by gay and bi men may play a role.

These results highlight the importance of including questions about sexual orientation and gender identity in health surveys, according to lead study author Dr. Arash Mostaghimi, a dermatologist at Brigham and Women’s Hospital in Boston.

Mostaghimi and his team looked at links between sexual identity and gender identity and the lifetime prevalence of skin cancer in the United States, the Reporter reports. 

Around 3.3 million people are diagnosed with skin cancer each year, making it by far the most common type of cancer, according to the American Cancer Society. Although most skin cancer can be removed or treated, melanoma — which accounts for about 1 percent of all cases — can be deadly. 

As described in the medical journal JAMA Dermatology, Mostaghimi’s first study analyzed data from 2014-2018 from approximately 351,000 straight men, 7,500 gay men, 5,000 bisexual men, 466,000 straight women, 9,400 bi women and 5,400 lesbians, the Reporter reports. 

The researchers found that 8.1 percent of gay men and 8.4 percent of bi men reported that they had ever had skin cancer, both significantly higher than the 6.7 percent rate among straight men. After adjusting for other factors, gay men were 26 percent more likely and bi men were 48 percent more likely to have had skin cancer than straight men, the Reporter reports. 

Among women, 6.6 percent of straight women, 5.9 percent of lesbians and 4.7 percent of bi women reported ever having skin cancer. Bi women were 22 percent less likely to have had skin cancer than straight women, the Reporter reports. 

Continue Reading

Follow Us @washblade

Sign Up for Blade eBlasts